Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01123785 · ClinicalTrials.gov registry record · Phase 1
A Dose-Escalation Study Designed to Evaluate the Tolerability, Safety, Pharmacokinetics (PK), and Efficacy of Chronic Topical Ocular Application of INO-8875 in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma
A Phase 1 study of Glaucoma and Ocular Hypertension, sponsored by Inotek Pharmaceuticals Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 144
- Enrollment target
- 1
- Study location
NCT01123785 is a Phase 1 study of Glaucoma and Ocular Hypertension that has completed, run by Inotek Pharmaceuticals Corporation. The registered enrollment target is 144 participants, below the 909-participant average among 92 other Glaucoma trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01123785, a Phase 1 study of Glaucoma and Ocular Hypertension, has completed, sponsored by Inotek Pharmaceuticals Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 144 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate how tolerable, safe, and effective it is to give INO-8875 eye drops to adults with glaucoma or ocular hypertension.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG INO-8875
Study Locations (1)
California
- Lugene Eye Institute - Glendale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 144 participants |
| Start Date | 2010-05 |
| Est. Completion | 2012-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01123785
The ClinicalTrials.gov registry entry for NCT01123785 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 144 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 909-participant average among 92 other Glaucoma trials with a reported enrollment target (84% lower). The listed sponsor is Inotek Pharmaceuticals Corporation, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Glaucoma appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01123785 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT01123785 about?
NCT01123785 is a clinical study titled "A Dose-Escalation Study Designed to Evaluate the Tolerability, Safety, Pharmacokinetics (PK), and Efficacy of Chronic Topical Ocular Application of INO-8875 in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma". The purpose of this study is to evaluate how tolerable, safe, and effective it is to give INO-8875 eye drops to adults with glaucoma or ocular hypertension.
What is the current status of trial NCT01123785?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 144 participants. The study started on 2010-05. Estimated completion is 2012-01.
What conditions does trial NCT01123785 study?
This clinical trial studies the following conditions: Glaucoma, Ocular Hypertension.
What interventions are being tested in trial NCT01123785?
The interventions under investigation include: Placebo (DRUG), INO-8875 (DRUG).
Who is sponsoring clinical trial NCT01123785?
This trial is sponsored by Inotek Pharmaceuticals Corporation, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01123785 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glaucoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Topical Insulin for Glaucoma
RECRUITING · Phase 1
-
Safety Assessment of T4090 Eye Drops in Ocular Hypertensive or Glaucomatous Patients.
ACTIVE NOT RECRUITING · Phase 1
-
Evaluation of the Bimatoprost Implant System Used in Combination With the SpyGlass Intraocular Lens Compared to Timolol Ophthalmic Solution
ACTIVE NOT RECRUITING · Phase 1
-
Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt
COMPLETED · Phase 1
-
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5093151 in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).
COMPLETED · Phase 1
-
Efficacy, Tolerability and Safety of RKI983 (0.05% & 0.10%) vs Xalatan in Patients With POAG or Ocular Hypertension
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.